Apollon Wealth Management LLC Makes New $43,000 Investment in PainReform Ltd. (NASDAQ:PRFX)

Apollon Wealth Management LLC purchased a new stake in PainReform Ltd. (NASDAQ:PRFX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 12,917 shares of the company’s stock, valued at approximately $43,000. Apollon Wealth Management LLC owned 9.23% of PainReform at the end of the most recent reporting period.

Analyst Ratings Changes

Separately, Maxim Group reiterated a “hold” rating on shares of PainReform in a report on Thursday, October 24th.

PainReform Trading Down 2.8 %

NASDAQ PRFX opened at $2.82 on Tuesday. The stock has a fifty day simple moving average of $3.42 and a 200-day simple moving average of $2.72. The stock has a market cap of $394,800.00, a PE ratio of -0.02 and a beta of 0.64. PainReform Ltd. has a twelve month low of $1.73 and a twelve month high of $61.20.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.